E160 - (CME) Novel Agents for Treating Major Depressive Disorder (MDD)
NEI Podcast
00:00
Psychedelics: What We Know So Far
Ketamine and then ketamine trials, if appropriately used, there doesn't seem to be any detrimental impact on the duration. Psilocybin did not demonstrate on primary measure a difference between the two. It is also a question of how we measure improvement in depression. So it may have different effects and effects that are not necessarily captured with standard scales.
Transcript
Play full episode
